Saturday, September 5

Browsing: PostNeoadjuvant

Support

97 monarchE: Evaluation of Prognostic and Predictive Value of Ki-67 Index Pre- and Post-Neoadjuvant Chemotherapy and Changes Following NAC

By NewsCancerMay 22, 20260

BackgroundTwo years of adjuvant abemaciclib plus endocrine therapy (ET) improved invasive disease-free survival (iDFS) over ET alone in patients with…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Browsing: PostNeoadjuvant

97 monarchE: Evaluation of Prognostic and Predictive Value of Ki-67 Index Pre- and Post-Neoadjuvant Chemotherapy and Changes Following NAC

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

Latest Post

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: PostNeoadjuvant